Immunovia announces completion of preferential rights issue

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 19, 2016 at 11:15 AM

Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee. 285,072 new shares, representing 86.5% of the rights issue of maximum 329,451 new shares, were subscribed with preferential rights. Demand for excess shares by rights holders amounted to 184,969 new shares, of which only 44,379 new shares could be allocated. The total demand for the offering amounted to approximately SEK 40.9 million, reflecting an oversubscription rate of 43%. The total amount, which is a record for a diagnostics company on Stockholm’s NASDAQ First North market, will be used primarily to initiate trials among diabetic patients which important new research shows are at high risk for pancreatic cancer. The trials will use Immunovia’s IMMrayTMPanCan-d blood -biomarker-based microarray test. Pancreatic cancer continues to have the lowest survival rates among the major forms of cancer. Today it is very clear that the main focus should be early detection of stages I & II pancreatic cancer in order to improve conditions for survival. Around 10% of pancreatic cancer cases have genetic and hereditary causes, and persons in this risk group can be clearly identified for regular surveillance. However, the vast majority (90%) of pancreatic cancer cases do not have the hereditary link and because the entire population cannot be monitored regularly, a first selection must be made. Immunovia CEO Mats Grahn commented: “Recent research shows that patients aged over 50 suffering from diabetes also have up to 8 times greater risk than normal of developing pancreatic cancer. There is a growing consensus that the size of this group makes it a logical target for surveillance. This has led both public authorities and health institutes in several countries to initiate research programs to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group. We believe PanCan -d provides the perfect diagnostic and surveillance tool and are already in active negotiations to bring together the various research strands into an international consortium.” The directed rights issue attracted several Swedish and Institutional investors including Handelsbanken Fonder, Ålandsbanken Fondbolag (which has been institutional investor in the company since the company's IPO in December 2015), E. Öhman J:or Fonder and Banque Internationale á Luxembourg. “We see these successful emmisions both as an indication of confidence in our technology and in our commercialization approach,” continued Grahn. “In additional to the diabetes program, we will deploy the new funds to expand the geographical markets in the commercialization of IMMrayTM PanCan-d for high risk individuals in familiar pancreatic cancer. A smaller portion will be used to develop tests from the IMMrayTM platform for other cancer forms and the autoimmune disease Lupus (SLE).” For further information, contact: Mats Grahn, CEO Immunovia AB Phone: +46 (0)70-532 02 30 E-mail: mats.grahn@immunovia.com About Immunovia Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Castillo Engineering Gears Up with New VP Appointments

New Leadership to Drive Expansion In a boost to its commitment to scaling up, Castillo Engineering, based in Maitland, Florida, has roped in two veterans from the renewables sector as vice presidents. Aaron Carrillo and Devin Radovich, who share a history of successful collaboration at Renewable Energy Systems Americas (RES), are set to guide Castillo's growth in the...

Navigating AI's New Era: Dresner's 2026 Findings

Big Insights in the AI World of 2026 Well folks, if there's one thing making waves in the boardrooms this year, it's AI. Dresner Advisory Services just threw down a gauntlet for companies with their fresh batch of reports focused on the dizzying world of AI. They ripped right into it, exploring how firms can bag a heap of benefits and deal with the hurdles that come with...

NACD Honors Top Board Leaders with 2026 Awards

Celebrating Boardroom Mavericks at NACD Gala September 2026 has brought some sparkling recognition to the elites guiding today's corporate governance landscapes. The National Association of Corporate Directors (NACD) has announced their Directorship 100 honorees, tipping their hats to stellar individuals firing on all cylinders in the boardroom. Who's Getting the Nod?...

U.N. Leaders Converge at NYSE, Forus Soars to $3B Valuation

A Busy Morning at the NYSE with Key Guests and Global Events In a world where high-stakes diplomacy and roaring market bells go hand in hand, today brings the U.S. Secretary of State, Marco Rubio, to the New York Stock Exchange. With the 81st Session of the United Nations General Assembly shaking up the Big Apple, the city finds itself at the intersection of politics and...

Molex's VersaBeam Mini Pushes AI Data Center Limits

Game-Changer for AI Data Centers? Across the tech landscape, space is a premium, and Molex's new VersaBeam Mini arrives like a hail Mary in the fourth quarter. In AI data centers, squeezing down every single component counts—especially when optical density's in play. What we're seeing here is a potential paradigm shift. A 3x density improvement from a tiny 3.5 x 9 mm...

Lawsuit Targets Electrical Consultants' Labor Practices

Trouble Brews at Electrical Consultants, Inc. Right on the heels of a long workday, some employees of Electrical Consultants, Inc. seem to be getting a double whammy. The company is tangled up in a class action lawsuit lodged by the well-known Blumenthal Nordrehaug Bhowmik De Blouw LLP. This ain't your everyday grievance, folks; we're talking meal and rest period...

Anixa Expands Global Footprint with Aussie Patent

Breaking New Ground in Cancer Immunotherapy Today feels like a pivotal day for Anixa Biosciences. Their announcement about securing a patent in Australia for their trailblazing breast cancer vaccine is like planting a flag on new, promising territory. This is no minor step; it's a strategic leap for the company as it strengthens its intellectual grip on the global...

Lititz Mutual Embraces AI with Guidewire ProNavigator

It's not every day you see a company like Lititz Mutual making moves in the artificial intelligence (AI) arena. Based out of Lititz, Pennsylvania, this insurance firm has decided to shake things up with Guidewire's ProNavigator AI assistant. Forging New Paths in Insurance Lititz Mutual is set to inject some serious tech into their operations. The goal? Make life easier...

Tenera Care's Tech Triumph: Halving Falls with Simplicity

Every once in a while, a piece of tech comes along that makes you sit up and say, ‘Now that’s a game-changer!’ And with the recent rave reviews, Tenera Care seems to hit just that sweet spot for folks in the senior living game. By handing Dublin Glenn Memory Care the gold in the KISS category at the 2026 McKnight's Technology Awards, it’s clear the industry is...

Lavior and CR Fitness Team for Wellness Reach

Botanical Care Meets Gym Life in the Southeast Lavior, the botanical whiz kids of wound and skin care out of Miami, are shaking hands with CR Fitness, Crunch's big-time franchise operator carrying the flag across the Southeast. They’ve ironed out a deal that’ll park Lavior’s products in more than 60 gyms covering Florida, Georgia, North Carolina, and Texas. It’s a...